German pharmaceutical company Bayer AG has formally lodged a challenge against a landmark Indian ruling that allowed a domestic generic drug-maker to produce a low-cost version of an anti-cancer drug for the Indian market. The appeal was filed on Friday 4 May with India's Intellectual Property Appellate Board.
Links:
[1] http://admin.indiaenvironmentportal.org.in/feature-article/bayer-challenges-india-compulsory-license-ruling
[2] http://admin.indiaenvironmentportal.org.in/category/journal/bridges-weekly-trade-news-digest
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/bayer-pharmaceuticals
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/india
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/germany
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/cancer
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/patents